| Leles, Claudio R |
SMIS, NCT04760457: Mandibular Overdentures Retained by Mini Implants: a Clinical Trial Comparing Different Surgical and Loading Protocols |
|
|
| Completed | N/A | 74 | RoW | Implant placement with flapped surgery, Implant placement with flapless surgery, Implant immediate loading, Implant delayed loading | Universidade Federal de Goias, ITI International Team for Implantology, Switzerland, Institut Straumann AG | Edentulous Mouth, Complete Edentulism | 11/22 | 11/22 | | |
NCT04605016: Clinical Performance of Dentals Implants With Hydrophilic or Hydrophobic Surfaces |
|
|
| Active, not recruiting | N/A | 44 | RoW | Hydrophilic surface implants, Neodent Helix Grand Morse® Acqua, Hydrophobic surface implants, Neodent Helix Grand Morse® Neoporos | Universidade Federal de Goias | Tooth Loss | 09/23 | 12/23 | | |
| Recruiting | N/A | 50 | RoW | Dual-cantilevered implant bridge, 3-unit iFDP | University of Bern, ITI International Team for Implantology, Switzerland | Dental Implant Failed | 10/25 | 10/26 | | |
| Schimmel, Martin |
NCT06138392: Long-term Study in Early Loaded Hydrophilic Surface Implants |
|
|
| Completed | N/A | 12 | Europe | Dental implant (ELEMENT RC INICELL, Thommen Medical) | University of Bern | Dental Implant | 09/21 | 12/21 | | |
SMIS, NCT04760457: Mandibular Overdentures Retained by Mini Implants: a Clinical Trial Comparing Different Surgical and Loading Protocols |
|
|
| Completed | N/A | 74 | RoW | Implant placement with flapped surgery, Implant placement with flapless surgery, Implant immediate loading, Implant delayed loading | Universidade Federal de Goias, ITI International Team for Implantology, Switzerland, Institut Straumann AG | Edentulous Mouth, Complete Edentulism | 11/22 | 11/22 | | |
| Active, not recruiting | N/A | 72 | Europe | early loading, immediate loading | University of Bern | Dental Implants | 09/24 | 08/33 | | |
NCT06335628: Volumetric Dimensional Changes After Surgical Pontic Site Development Procedures With Connective Tissue Graft or Collagen Matrix |
|
|
| Recruiting | N/A | 38 | Europe | Geistlich Fibro-Gide® | University of Bern | Connective Tissue Graft, Volume Collagen Matrix Xenograft | 04/26 | 04/29 | | |
| Recruiting | N/A | 50 | RoW | Dual-cantilevered implant bridge, 3-unit iFDP | University of Bern, ITI International Team for Implantology, Switzerland | Dental Implant Failed | 10/25 | 10/26 | | |
| East, Cara |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events |
|
|
| Active, not recruiting | 3 | 608 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Coronary Artery Disease | 01/27 | 01/27 | | |
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
|
|
| Active, not recruiting | 3 | 17004 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 10/27 | 10/27 | | |
GxRDxHTN, NCT04060641: Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension |
|
|
| Recruiting | N/A | 30 | US | Geneticure for RDN Genetic Panel | Geneticure, LLC | Hypertension | 05/22 | 09/22 | | |
| Junior, Ruffo Freitas |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
|
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Sala, Jorgelina Mariana |
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial |
|
|
| Completed | 3 | 731 | US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | 07/24 | 07/24 | | |
|
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Freitas, Aguinaldo F |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial |
|
|
| Completed | 3 | 731 | US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | 07/24 | 07/24 | | |
|
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
